DURATION-6 Top-Line Study Results Announced

March 14, 2011

Press release Eli Lilly

This open-label 26-week, multicenter clinical study compared BYDUREON (2 mg weekly) to Victoza administered at the maximum approved dose of 1.8 mg daily.

The study was designed to measure A1C, an assessment of average blood sugar, and to evaluate safety and tolerability.

Results showed that patients receiving BYDUREON experienced a reduction in A1C of 1.3 percentage points from baseline, compared to a reduction of 1.5 percentage points for Victoza. BYDUREON did not meet the pre-specified primary endpoint of non-inferiority to Victoza.

Article information
Pharmaceutical industry
Eli Lilly
March 14, 2011
Free HCP newsletter
Join the newsletter
Free weekly news
Latest diabetes healthcare news direct to your inbox.
NHS employee:
Latest forum posts
The latest forum threads from the Ask a Question forum.
Healthcare Search